Irene Moreno Torres (@irenemorenot) 's Twitter Profile
Irene Moreno Torres

@irenemorenot

MD Neurologist, MSc Neuroimmunology, PhD in Neurosciences

ID: 116904363

calendar_today23-02-2010 23:12:59

417 Tweet

378 Takipçi

690 Takip Edilen

Georgina Arrambide (@geoarrambide) 's Twitter Profile Photo

ECTRIMS 2024 opening ceremony with the Queen of Denmark present, a beautiful video on the history of ECTRIMS now celebrating its 40th anniversary, and a great ECTRIMS lecture by Jackie Palace on NMOSD and MOGAD. #ECTRIMS2024 ECTRIMS Mar Tintore

ECTRIMS 2024 opening ceremony with the Queen of Denmark present, a beautiful video on the history of ECTRIMS now celebrating its 40th anniversary, and a great ECTRIMS lecture by Jackie Palace on NMOSD and MOGAD. #ECTRIMS2024 <a href="/ECTRIMS/">ECTRIMS</a> <a href="/MarTintore/">Mar Tintore</a>
Barry Singer MD 🧠 (@drbarrysinger) 's Twitter Profile Photo

New McDonald Criteria for diagnosis MS. Xavier Montalban: New criteria includes RIS under certain circumstances, central vein sign, neurofilament light chain and optic nerve. #ECTRIMS2024

New McDonald Criteria for diagnosis MS. <a href="/XMontalban/">Xavier Montalban</a>: New criteria includes RIS under certain circumstances, central vein sign, neurofilament light chain and optic nerve.  #ECTRIMS2024
Lea Alhilali, MD (@teachplaygrub) 's Twitter Profile Photo

1/Have MULTIPLE questions about the new criteria for MULTIPLE sclerosis? ECTRIMS 2024 just came out w/proposed new changes to the McDonald criteria for multiple sclerosis. The changes are complex, but here is a thread w/the basics that you NEED to know!

1/Have MULTIPLE questions about the new criteria for MULTIPLE sclerosis?

ECTRIMS 2024 just came out w/proposed new changes to the McDonald criteria for multiple sclerosis.

The changes are complex, but here is a thread w/the basics that you NEED to know!
Dr. Brandon Beaber (@brandon_beaber) 's Twitter Profile Photo

Ocrevus and rituximab don't work in primary progressive MS? This French Observational study of 1,184 people found those taking these drugs had similar rates of disability progression (when correcting for other confounders) than people not taking them. neurology.org/doi/10.1212/WN…